File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.neuropharm.2011.11.012
- Scopus: eid_2-s2.0-84856429809
- PMID: 22146407
- WOS: WOS:000301221500007
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Potential roles of PI3K/Akt and Nrf2-Keap1 pathways in regulating hormesis of Z-ligustilide in PC12 cells against oxygen and glucose deprivation
Title | Potential roles of PI3K/Akt and Nrf2-Keap1 pathways in regulating hormesis of Z-ligustilide in PC12 cells against oxygen and glucose deprivation |
---|---|
Authors | |
Keywords | Heme oxygenase-1 Hormetic effect Nrf2 pathway Oxygen glucose deprivation PI3K Z-ligustilide |
Issue Date | 2012 |
Publisher | Pergamon. The Journal's web site is located at http://www.elsevier.com/locate/neuropharm |
Citation | Neuropharmacology, 2012, v. 62 n. 4, p. 1659-1670 How to Cite? |
Abstract | Many phytochemicals may ameliorate neurological disorders through a hormetic mechanism. The aim of this study was to characterize the hormetic role of Z-ligustilide in PC12 cells against oxygen glucose deprivation (OGD) induced cell death. We examined the interactions of Z-ligustilide with the pro-survival signals mediated by phosphatidylinositol 3-kinase (PI3K) and transcription factor nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) pathways. We also investigated the effect of Z-ligustilide on the intracellular redox signaling system involving reactive oxygen species (ROS) and glutathione (GSH). Z-ligustilide not only triggered stress response by causing ROS formation and transient GSH depletion, but also activated survival-promoting signals via cross-talking of PI3K and Nrf2 pathways. A key finding was that Z-ligustilide preconditioning protected PC12 cells from OGD-induced injury either at a low concentration for a prolonged period of time or at a high concentration for a short period of time. Presumably, mild preconditioning stimulated moderate ROS production, but effectively activated hormetic signals and induced stress responsive genes. In contrast, higher concentrations of Z-ligustilide could be toxic over a prolonged period of time due to massive ROS production. These results suggest that the effect of Z-ligustilide may be regulated by a biphasic hormetic mechanism involving initial induction of oxidative stress and subsequent activation of stress response gene expression. © 2011 Elsevier Ltd. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/160719 |
ISSN | 2023 Impact Factor: 4.6 2023 SCImago Journal Rankings: 1.489 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Qi, H | en_HK |
dc.contributor.author | Han, Y | en_HK |
dc.contributor.author | Rong, J | en_HK |
dc.date.accessioned | 2012-08-16T06:17:19Z | - |
dc.date.available | 2012-08-16T06:17:19Z | - |
dc.date.issued | 2012 | en_HK |
dc.identifier.citation | Neuropharmacology, 2012, v. 62 n. 4, p. 1659-1670 | en_HK |
dc.identifier.issn | 0028-3908 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/160719 | - |
dc.description.abstract | Many phytochemicals may ameliorate neurological disorders through a hormetic mechanism. The aim of this study was to characterize the hormetic role of Z-ligustilide in PC12 cells against oxygen glucose deprivation (OGD) induced cell death. We examined the interactions of Z-ligustilide with the pro-survival signals mediated by phosphatidylinositol 3-kinase (PI3K) and transcription factor nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) pathways. We also investigated the effect of Z-ligustilide on the intracellular redox signaling system involving reactive oxygen species (ROS) and glutathione (GSH). Z-ligustilide not only triggered stress response by causing ROS formation and transient GSH depletion, but also activated survival-promoting signals via cross-talking of PI3K and Nrf2 pathways. A key finding was that Z-ligustilide preconditioning protected PC12 cells from OGD-induced injury either at a low concentration for a prolonged period of time or at a high concentration for a short period of time. Presumably, mild preconditioning stimulated moderate ROS production, but effectively activated hormetic signals and induced stress responsive genes. In contrast, higher concentrations of Z-ligustilide could be toxic over a prolonged period of time due to massive ROS production. These results suggest that the effect of Z-ligustilide may be regulated by a biphasic hormetic mechanism involving initial induction of oxidative stress and subsequent activation of stress response gene expression. © 2011 Elsevier Ltd. All rights reserved. | en_HK |
dc.language | eng | en_US |
dc.publisher | Pergamon. The Journal's web site is located at http://www.elsevier.com/locate/neuropharm | en_HK |
dc.relation.ispartof | Neuropharmacology | en_HK |
dc.subject | Heme oxygenase-1 | - |
dc.subject | Hormetic effect | - |
dc.subject | Nrf2 pathway | - |
dc.subject | Oxygen glucose deprivation | - |
dc.subject | PI3K | - |
dc.subject | Z-ligustilide | - |
dc.subject.mesh | 4-Butyrolactone - analogs & derivatives - pharmacology | en_HK |
dc.subject.mesh | Animals | en_HK |
dc.subject.mesh | Anoxia - metabolism | en_HK |
dc.subject.mesh | Glucose - deficiency | en_HK |
dc.subject.mesh | Heme Oxygenase-1 - metabolism | en_HK |
dc.subject.mesh | Hormesis - physiology | en_HK |
dc.subject.mesh | NF-E2-Related Factor 2 - metabolism | en_HK |
dc.subject.mesh | Oxidative Stress - drug effects | en_HK |
dc.subject.mesh | PC12 Cells | en_HK |
dc.subject.mesh | Phosphatidylinositol 3-Kinases - metabolism | en_HK |
dc.subject.mesh | Proteins - metabolism | en_HK |
dc.subject.mesh | Proto-Oncogene Proteins c-akt - metabolism | en_HK |
dc.subject.mesh | Rats | en_HK |
dc.subject.mesh | Reactive Oxygen Species - metabolism | en_HK |
dc.subject.mesh | Signal Transduction - drug effects | en_HK |
dc.title | Potential roles of PI3K/Akt and Nrf2-Keap1 pathways in regulating hormesis of Z-ligustilide in PC12 cells against oxygen and glucose deprivation | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Rong, J: jrong@hku.hk | en_HK |
dc.identifier.authority | Rong, J=rp00515 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.neuropharm.2011.11.012 | en_HK |
dc.identifier.pmid | 22146407 | - |
dc.identifier.scopus | eid_2-s2.0-84856429809 | en_HK |
dc.identifier.hkuros | 203764 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-84856429809&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 62 | en_HK |
dc.identifier.issue | 4 | en_HK |
dc.identifier.spage | 1659 | en_HK |
dc.identifier.epage | 1670 | en_HK |
dc.identifier.eissn | 1873-7064 | - |
dc.identifier.isi | WOS:000301221500007 | - |
dc.publisher.place | United Kingdom | en_HK |
dc.identifier.scopusauthorid | Qi, H=35367105300 | en_HK |
dc.identifier.scopusauthorid | Han, Y=8527680500 | en_HK |
dc.identifier.scopusauthorid | Rong, J=7005980047 | en_HK |
dc.identifier.citeulike | 10103162 | - |
dc.identifier.issnl | 0028-3908 | - |